Long-term treatment with glucagon-like peptide-1 receptor activators improves blood sugar control and lowers overall death risk compared to dipeptidyl peptidase-4 inhibitors in type 2 diabetes

The probability of any HbA1c improvement at 1 year was 82.7% with sustained GLP-1 RA use compared to 67.1% with DPP-4 inhibitors.

• Sustained GLP-1 RA use was linked to a 15.7% higher probability of HbA1c improvement compared to DPP-4 inhibitors.
• Patients using GLP-1 RAs experienced lower all-cause mortality risk, with a 0.4% reduction at 1 year and a 1.1% reduction at 3 years.
• The study included 16,619 GLP-1 RA initiators and 34,196 DPP-4i initiators, with an average of 2.8 HbA1c measurements per patient-year.
• Findings suggest that GLP-1 RAs may provide better glycemic control and a modest mortality benefit over DPP-4 inhibitors.

Simplified